AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma
AdvanTIG-206:一项II期随机研究,比较奥西哌利单抗联合替雷利珠单抗和BAT1706(贝伐珠单抗生物类似药)与替雷利珠单抗联合BAT1706一线治疗肝细胞癌的疗效。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-026-04399-8
Ren, Zhenggang; Huang, Yao; Guo, Yabing; Hou, Ming-Mo; Wang, Wei; Kuang, Ming; Hao, Chunyi; Wang, Wentao; Zhang, Yanqiao; Song, Tianqiang; Dai, Chaoliu; Kuo, Hsing-Tao; Bao, Zinan; Zuo, Yunxia; Wang, Lei; Zhu, Fuxiang; Fan, Jia